文献速递瓣膜外科

继发性二尖瓣反流:外科修复与经导管缘对缘修复的倾向性评分匹配队列比较

Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-07-28

该回顾性多中心队列纳入继发性二尖瓣反流患者,经1:1倾向性评分匹配后比较经导管缘对缘修复(TMVr)与外科二尖瓣修复(SMVr)。两组2年全因死亡率无显著差异,但SMVr组二尖瓣反流减少更显著且持久,并伴随左心室射血分数(LVEF)改善。

要点

  • 匹配后TMVr与SMVr的2年全因死亡率无显著差异。
  • SMVr组出院及2年时二尖瓣反流降至无或轻度的比例更高。
  • SMVr组LVEF显著改善,TMVr组未见明显变化。

核心结论

  • 在倾向性评分匹配分析中,TMVr与SMVr的2年生存率无显著差异,但SMVr组二尖瓣反流减少更显著且持久,并伴随LVEF改善。

研究设计与样本

  • 回顾性多中心队列研究,纳入连续接受TMVr(n=199)或SMVr(n=222)的继发性二尖瓣反流患者,并进行1:1倾向性评分匹配,匹配后共202例患者。

临床怎么用

  • 对于继发性二尖瓣反流患者,TMVr与SMVr的2年生存率相当,但SMVr在减少二尖瓣反流和改善LVEF方面更优,临床决策需综合评估手术风险与获益。

局限性

  • 本研究为回顾性分析,尽管采用倾向性评分匹配,仍可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy and clinical outcomes of transcatheter edge-to-edge mitral valve repair (TMVr) and surgical mitral valve repair (SMVr) among patients with secondary mitral regurgitation (SMR). METHODS: Consecutive patients with SMR treated using either TMVr (n = 199) or SMVr (n = 222) at 2 centers were included and retrospectively analyzed. To account for differences in patient demographic characteristics, 1:1 propensity score matching was performed. The primary endpoint was all-cause death within 2 years after the procedure. RESULTS: The study population consisted of 202 matched patients. At 2 years, all-cause mortality was 24.3% for TMVr and 23.0% for SMVr (hazard ratio, 0.97; 95% confidence interval, 0.55-1.71; P = .909). Severe heart failure symptoms at 2 years were less prevalent after SMVr (New York Heart Association functional class III or IV: 13.5% vs 29.5%; P = .032) than after TMVr. A higher proportion of the SMVr patients had SMR reduction to none or mild at discharge (90.8% vs 72.0%; P < .001) and 2 years (86.5% vs 59.6%; P < .001). Among patients who achieved none or mild MR at discharge, 7 patients (10.1%) in the SMVr group and 15 (34.9%) in the TMVr group had progression to moderate or greater MR at 2 years (P = .003). Left ventricular ejection fraction (LVEF) significantly improved (+10.1% ± 11.1%; P < .001) after SMVr (LVEF at 2 years: 45.7% ± 12.8%), whereas it remained unchanged (-1.3% ± 8.9%; P = .260) after TMVr (LVEF at 2 years: 34.0% ± 13.2%). CONCLUSIONS: In this propensity score-matched analysis, there was no significant difference in 2-year survival between TMVr and SMVr, despite greater and more durable SMR reduction, as well as LVEF improvement in the surgical group.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Okuno T, Praz F, Kassar M, et al. Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. J Thorac Cardiovasc Surg. 2021. PMID: 34446288. doi:10.1016/j.jtcvs.2021.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。